Prof. Dr. med. Martin W. Bergmann

2005 Oberarzt, Herzkatheter Franz-Volhard-Klinik, Charité Campus Buch, Berlin

2008 stellvertretender Leiter & Leitender Oberarzt Abt. Kardiologie, Asklepios Klinik St. Georg

2014 Gesellschafter Cardiologicum Hamburg

2014 Leiter des Katheterlabors Cardiologicum / Asklepios Klinik Wandsbek

2016 Konsiliararzt Abt. Kardiologie, Asklepios Klinik St. Georg

2019 Chefarzt Abt. Innere Medizin Kardiologie/Pneumologie Asklepios Klinik Wandsbek

2020 Chefarzt Kardiologie, Pneumologie & internistische Intensivmedizin, Asklepios Klinik Altona

1993 Studium der Humanmedizin Christian-Albrechts-Universität zu Kiel

1996 AiP/wissenschaftlicher Assistent, I. Medizinische Universitätsklinik Christian-Albrechts-Universität zu Kiel

1998 Ausbildungsstipendium Deutsche Forschungsgemeinschaft

Dep. of Molecular Pharmacology, Prof. Peter J. Barnes, National Heart & Lung Institute, Imperial College London

1998 DFG Forschungsstipendium

National Heart & Lung Institute/Imperial College/London

2004 wissenschaftlicher Assistent, Franz-Volhard-Klinik, Charité Campus Berlin-Buch, Prof. Dr. Rainer Dietz, Prof. Dr. Friedrich Luft & Prof. D. Ganten

2005 Helmholtz-Stipendiat

Charité Campus Buch & Max Delbrück Centrum für Molekulare Medizin Berlin

Arbeitsgruppe Interventionelle Kardiologie der DGK

Deutsche Gesellschaft für Kardiologie

European Association of Percutaneous Cardiac Interventions (EAPCI)

Faculty EuroPCR Course

Faculty Transcatheter Cardiovascular Therapeutics (TCT)

Klinische Kommission der Deutschen Gesellschaft für Kardiologie

Fellow der European Society of Cardiology

Zusatzbezeichnung spezielle, internistische Intensivmedizin

Zusatzqualifikation Herzinsuffizienz

Zusatzqualifikation interventionelle Kardiologie

Grundlagenforschung Herzinsuffizienz und kardiale Regeneration

Grundlagenforschung molekulare Signaltransduktion

Interventionelle Kardiologie: PCI & invasive Bildgebung

Strukturelle Herzerkrankungen: TAVI, LAA-Verschluss, inter-atriale Shunts

2007 Winterstein Preis der Deutschen Herzstiftung

2013 Forschungspreis der Asklepios Kliniken

European Socienty of Cardiology

Analysis of Immunoglobulins in Sarcoidosis

Bergmann, M., S. Jonasson, N. Klause, F. Engler, D. Kirsten, and J. Barth (1997). Analysis of Immunoglobulins in Sarcoidosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 14: 105-208

Evidence for involvement of NF-B in the transcriptional control of COX-2 gene expression by IL-1

Newton, L.M.E. Kuitert, M. Bergmann, I.M. Adcock, P.J. Barnes. Evidence for involvement of NF-B in the transcriptional control of COX-2 gene expression by IL-1. Biochem. Biophys. Res. Commun. 1997; 237:28-32

B degradation and nuclear factor-B DNA binding are insufficient for interleukin-1 and tumor necrosis factor- induced B-dependent transcription

M. Bergmann, L.Hart, M.Lindsay, P.J. Barnes, R. Newton. IB degradation and nuclear factor-B DNA binding are insufficient for interleukin-1 and tumor necrosis factor- induced B-dependent transcription. J Biol Chem 1998, 273:6607-6610 SCI 123

Effect of dexamethasone on IL-1 -induced NF-B and B-dependent transcription in epithelial cells

R. Newton, L.A. Hart, D.A. Stevens, M. Bergmann, L.E. Donnelly, I.M. Adcock, P.J. Barnes. Effect of dexamethasone on IL-1 -induced NF-B and B-dependent transcription in epithelial cells. Eur J Biochem 1998, 254:81-89 SCI 8

Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation

M. Bergmann, A. Tiroke, H. Schafer, J. Barth, and A. Haverich. Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation. Scand.Cardiovasc.J 1998; 32 (2):97-103 SCI 18

Repression of COX-2 and PGE2 Release by Dexamethasone Occurs by Transcriptional and Post-transcriptional Mechanisms Involving Loss of Polyadenylated mRNA

Newton, J. Seybold, LM E. Kuitert, M. Bergmann, P. J. Barnes. Repression of COX-2 and PGE2 Release by Dexamethasone Occurs by Transcriptional and Post-transcriptional Mechanisms Involving Loss of Polyadenylated mRNA. J Biol Chem 1998; 273:32312-32321

Molecular Regulation of Granulocyte-Macrophage Colony-Stimulating Factor in Human Lung Epithelial Cells by Interleukin (IL)-1beta, IL-4, and IL-13 Involves Both Transcriptional and Post-Transcriptional Mechanisms

Bergmann, P. J. Barnes, and R. Newton. Molecular Regulation of Granulocyte-Macrophage Colony-Stimulating Factor in Human Lung Epithelial Cells by Interleukin (IL)-1beta, IL-4, and IL-13 Involves Both Transcriptional and Post-Transcriptional Mechanisms. Am.J.Respir.Cell Mol.Biol.2000; 22:582.-589

Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action

J. Staples, M. Bergmann, P. J. Barnes, and R. Newton. Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action. Biochem.Biophys.Res.Commun. 2000; 273 (3):811-815

Adenosine 3',5'-Cyclic Monophosphate (cAMP)-Dependent Inhibition of IL- 5 from Human T Lymphocytes Is Not Mediated by the cAMP-Dependent Protein Kinase A

Staples KJ, Bergmann M, Tomita K, Houslay MD, McPhee I, Barnes PJ, Giembycz MA, Newton R. Adenosine 3',5'-Cyclic Monophosphate (cAMP)-Dependent Inhibition of IL- 5 from Human T Lymphocytes Is Not Mediated by the cAMP-Dependent Protein Kinase A. J.Immunol. 2001;167:2074-2080.

Effect of NF- kappa B Inhibition on TNF- alpha -induced Apoptosis and Downstream Pathways in Cardiomyocytes

Bergmann MW, Loser P, Dietz R, Harsdorf R. Effect of NF- kappa B Inhibition on TNF- alpha -induced Apoptosis and Downstream Pathways in Cardiomyocytes. J.Mol.Cell Cardiol. 2001;33:1223-1232.

GM-CSF expression in pulmonary epithelial cells is regulated negatively by posttranscriptional mechanisms

Newton R, Staples KJ, Hart L, Barnes PJ, Bergmann MW. GM-CSF expression in pulmonary epithelial cells is regulated negatively by posttranscriptional mechanisms. Biochem Biophys Res Commun. 2001;287:249-53.

In Cardiomyocyte Hypoxia, IGF-I-Induced Antiapoptotic Signaling Requires PI3-kinase- Dependent and MAPK-Dependent Activation of the Transcription Factor CREB

Mehrhof FB, Muller FU, Bergmann MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R. In Cardiomyocyte Hypoxia, IGF-I-Induced Antiapoptotic Signaling Requires PI3-kinase- Dependent and MAPK-Dependent Activation of the Transcription Factor CREB. Circulation. 2001;104:2088-2094.

Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone

Staples KJ, Bergmann MW, Barnes PJ, Newton R. Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. Immunology. 2003;109:527-535.

IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase

Catley MC, Chivers JE, Cambridge LM, Holden N, Slater DM, Staples KJ, Bergmann MW, Loser P, Barnes PJ, Newton R. IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett. 2003;547:75-79.

. Dexamethason inhibits T-cell GM-CSF release independent of NF-B. Role of post-transcriptional mechanisms

Bergmann MW, Staples KJ, Hart L, Barnes PJ, Newton R. Dexamethason inhibits T-cell GM-CSF release independent of NF-B. Role of post-transcriptional mechanisms. Immunology 2004; 111: 430-434

Glucocorticoid inhibition of GM-CSF from T cells is independent of control by NF-{kappa}B and CLE0

Bergmann, M. W., K. J. Staples, Smith SJ, Barnes PJ, Newton R. 'Glucocorticoid inhibition of GM-CSF from T cells is independent of control by NF-{kappa}B and CLE0.' Am J Respir Cell Mol Biol. 2004; 30:555-563

Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: Activation of CREB downstream of GSK3

El Jamali A, Freund C, Rechner C, Scheidereit C, Dietz R, Bergmann MW: Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: Activation of CREB downstream of GSK3. FASEB J 2004, 18: 1096 – 98

Statins inhibit cardiomyocyte apoptosis by inhibition of GSK3: stabilization of -catenin

Bergmann MW, Rechner C., Freund C. , El Jamali A., Dietz R.: Statins inhibit cardiomyocyte apoptosis by inhibition of GSK3: stabilization of -catenin. J Mol Cell Cardiol, 2004; 37:681-90

Requirement of NF-B in angiotensin II- and isoproterenol- induced cardiac hypertrophy in vivo

Freund, R. Schmidt-Ullrich , W. Schneider, P. Loser, A. El-Jamali, R. Dietz, C. Scheidereit , M.W. Bergmann. Requirement of NF-B in angiotensin II- and isoproterenol- induced cardiac hypertrophy in vivo. Circulation 2005; 111:317-23

-catenin downregulation is required for adaptive cardiac remodeling

Baurand, L. Zelarayan, R. Betney, C. Gehrke, S. Dunger, C. Noack, A. Busjahn, J. Huelsken, M.M. Taketo, R. Dietz, M.W. Bergmann. -catenin downregulation is required for adaptive cardiac remodeling. Circ Res 2007, 100: 1353-62

Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation

Zelarayan LC, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, van der Nagel R, Dietz R, de Windt LJ, Balligand JL, Bergmann MW. Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci U S A. 2008;105:19762-19767.

MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload

Hamid el Azzouzi; Ralph J van Oort; Roel van der Nagel; Wim Sluiter; Martin W Bergmann, Leon J. de Windt: MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. European Journal of Heart Failure 2009, 12:4-12

NF-{kappa}B activation is required for adaptive cardiac hypertrophy

Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW. NF-{kappa}B activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 2009; 84: 416-24

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the abciximab intracoronary versus intravenously drug application in st-elevation myocardial infarction (aida stemi) trial

Thiele H, Wohrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the abciximab intracoronary versus intravenously drug application in st-elevation myocardial infarction (aida stemi) trial. American Heart Journal. 2010;159:547-554

Chronic, low-dose epoetin- following PCI attenuates left ventricular remodeling in patients with ischemic cardiomyopathy

Martin W. Bergmann, Sven Haufe, Florian von Knobelsdorff-Brenckhahn, Heidrun Mehling, Ralf Waßmuth, Ines Münch, Andreas Busjahn, Jeanette Schulz-Menger, J. Jordan, , Friedrich C. Luft, Rainer Dietz: Chronic, low-dose epoetin- following PCI attenuates left ventricular remodeling in patients with ischemic cardiomyopathy. Eur J Heart Failure 2011, 13:560-568

Krueppel-like factor 15 regulates Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart

Claudia Noack, Maria-Patapia Zafiriou, Hans-Jörg Schäffer, Anke Renger, Elena Pavlova, Rainer Dietz, Wolfram H. Zimmermann, Martin W. Bergmann and Laura C. Zelarayán: Krueppel-like factor 15 regulates Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart. EMBO Mol Med 2012; 4:1-17

Delivery of a bioresorbable vascular scaffold to complex lesions

Delivery of a bioresorbable vascular scaffold to complex lesions. Meincke, F., K. H. Kuck, M.W. Bergmann. Catheter Cardiovasc Interv. 2013; 10.1002/ccd.25105

New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN device in patients not taking warfarin

New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN device in patients not taking warfarin. Meincke F, Schmidt-Salzmann M, Kreidel F, Kuck KH, Bergmann MW. EuroIntervention 2013, 9:1-6

Percutaneous left-ventricular support with the impella-2.5-assist device in acute cardiogenic shock: Results of the impella-euroshock-registry

Lauten A, Engstrom AE, Jung C, Empen K, Erne P, Cook S, Windecker S, Bergmann MW, Klingenberg. R, Luscher TF, Haude M, Rulands D, Butter C, Ullman B, Hellgren L, Modena MG, Pedrazzini G, Henriques JP, Figulla HR, Ferrari M. Percutaneous left-ventricular support with the impella-2.5-assist device in acute cardiogenic shock: Results of the impella-euroshock-registry. Circ Heart Fail. 2013;6:23-30

The four and a half lim-domain 2 controls early cardiac cell commitment and expansion via regulating beta-catenin-dependent transcription

Renger A, Zafiriou MP, Noack C, Pavlova E, Becker A, Sharkova K, Bergmann MW, El-Armouche A, Zimmermann WH, Zelarayan LC. The four and a half lim-domain 2 controls early cardiac cell commitment and expansion via regulating beta-catenin-dependent transcription. Stem cells. 2013;31:928-940

Cardiac tamponade due to coronary perforation during percutaneous interventions successfully treated with microspheres

Cardiac tamponade due to coronary perforation during percutaneous interventions successfully treated with microspheres. Meincke F, Kuck KH, Bergmann MW. Clin Res Cardiol. 2014; 103:325-7

Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques

Bergmann MW and Landmesser U. Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. EuroIntervention. 2014;10:497-504.

Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus

Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus. Meincke F, Kreidel F, von Wedel J, Schäfer U, Kuck KH, Bergmann MW. EuroIntervention. 2014; Epub ahead of print PMID:24642583

Results of the ALSTER BP Real World Registry on renal denervation employing the SYMPLICITY system

Results of the ALSTER BP Real World Registry on renal denervation employing the SYMPLICITY system. Lukas Kaiser MD, T. Beister, A. Wiese MD, J. von Wedel MD, F Meincke MD, F. Kreidel MD, A. Busjahn PhD*, Prof. K.H. Kuck MD, Prof. M.W. Bergmann MD; EuroIntervention 2014; 20: 157-65

Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry

Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry. Akin I, Nienaber CA, Richardt G, Tölg R, Hochadel M, Schneider S, Senges J, Tebbe U, Zeymer U, Sabin G, Kuck KH, Bergmann MW. Clin Res Cardiol. 2014; 103:363-72

EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Stein KM and Bergmann MW. EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv. 2015.

Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data

Gyongyosi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moye LA, Surder D, Corti R, Huikuri H, Miettinen J, Wohrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G and Investigators A. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-60

Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by Balloon-Based and Nonballoon-Based Renal Denervation Systems

Karanasos A, Van Mieghem N, Bergmann MW, Hartman E, Ligthart J, van der Heide E, Heeger CH, Ouhlous M, Zijlstra F, Regar E and Daemen J. Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by Balloon-Based and Nonballoon-Based Renal Denervation Systems. Circ Cardiovasc Interv. 2015;8:e002474.

Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus

Meincke F, Kreidel F, von Wedel J, Schafer U, Kuck KH and Bergmann MW. Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus. EuroIntervention. 2015;10:1208.

Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study

Verheye S, Ormiston J, Bergmann MW, Sievert H, Schwindt A, Werner N, Vogel B and Colombo A. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention. 2015;10:1221-9.

Very Late Scaffold Thrombosis Due to Insufficient Strut Apposition

Meincke F, Spangenberg T, Heeger CH, Bergmann MW, Kuck KH and Ghanem A. Very Late Scaffold Thrombosis Due to Insufficient Strut Apposition. JACC Cardiovasc Interv. 2015;8:1768-9.

Delayed coverage of drug-eluting stents after interventional revascularisation of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Heeger CH, Busjahn A, Hildebrand L, Fenski M, Lesche F, Meincke F, Kuck KH and Bergmann MW. Delayed coverage of drug-eluting stents after interventional revascularisation of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry. EuroIntervention. 2016;11:1004-12.

Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016 rapid publication

Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry

Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016 rapid publication

Safety and efficacy of lesion preparation with the AngioSculpt Scoring Balloon in left main interventions: the ALSTER Left Main registry

Schmidt T, Hansen S, Meincke F, Frerker C, Kuck KH, Bergmann MW. Safety and efficacy of lesion preparation with the AngioSculpt Scoring Balloon in left main interventions: the ALSTER Left Main registry. EuroIntervention 2016;11(12):1346-54.

Clinical Cases in LAA Occlusion

Bergmann M.W., Tzikas A, Wunderlich N. Clinical Cases in LAA Occlusion. Springer Nature: Springer International Book Publishing AG; 2017.

Improved Algorithm for Ostium Size Assessment in Watchman Left Atrial Appendage Occlusion Using Three-Dimensional Echocardiography

Schmidt-Salzmann M, Meincke F, Kreidel F, Spangenberg T, Ghanem A, Kuck KH, Bergmann MW. Improved Algorithm for Ostium Size Assessment in Watchman Left Atrial Appendage Occlusion Using Three-Dimensional Echocardiography. J Invasive Cardiol 2017;29(7):232-238.

Investigators E. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Foley D, Sievert H, Mazzone P, De Potter T, Vireca E, Stein K, Bergmann MW, Investigators E. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 2017;14(9):1302-1308.

Oral anticoagulation and platelet inhibition after atrial appendage occlusion

Bergmann MW, Israel CW. [Oral anticoagulation and platelet inhibition after atrial appendage occlusion]. Herzschrittmacherther Elektrophysiol 2017;28(4):388-394.

The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial

Holmes DR, Reddy VY, Buchbinder M, Stein K, Elletson M, Bergmann MW, Schmidt B, Saw J. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. Am Heart J 2017;189:68-74.

Trends Cardiovasc Med

Bergmann MW. LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. Trends Cardiovasc Med 2017;27(6):435-446.

European registry data on LAA closure: advancing the field of interventional stroke prevention

Bergmann MW. European registry data on LAA closure: advancing the field of interventional stroke prevention. EuroIntervention 2018;14(2):135-138.

European registry data on LAA closure: advancing the field of interventional stroke prevention

Bergmann MW. European registry data on LAA closure: advancing the field of interventional stroke prevention. EuroIntervention 2018;14(2):135-138.

Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study

Schmidt B, Betts TR, Sievert H, Bergmann MW, Kische S, Pokushalov E, Schmitz T, Meincke F, Mazzone P, Stein KM, Ince H, Boersma LVA. Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study. J Cardiovasc Electrophysiol 2018.

Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study

Schmidt B, Betts TR, Sievert H, Bergmann MW, Kische S, Pokushalov E, Schmitz T, Meincke F, Mazzone P, Stein KM, Ince H, Boersma LVA. Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study. J Cardiovasc Electrophysiol 2018;29(7):973-978.

Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome

Heeger CH, Schedifka AS, Meincke F, Spangenberg T, Wienemann H, Kreidel F, Kuck KH, Ghanem A, Bergmann MW. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry. Cardiol J 2018;25(4):459-469.

Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study

Bergmann MW, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B, Foley D, Betts TR, Grygier M, Protopopov AV, Stein KM, Boersma LVA. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention 2018;13(17):2003-2011.

Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study

Bergmann MW, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B, Foley D, Betts TR, Grygier M, Protopopov AV, Stein KM, Boersma LVA. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention 2018;13(17):2003-2011.

Three-months optical coherence tomography analysis of a biodegradable polymer, sirolimus-eluting stent

Kretov capital Ie C, Naryshkin I, Baystrukov V, Grazhdankin I, Prokhorikhin A, Zubarev D, Biryukov A, Verin V, Boykov A, Malaev D, Pokushalov E, Romanov A, Bergmann MW. Three-months optical coherence tomography analysis of a biodegradable polymer, sirolimus-eluting stent. J Interv Cardiol 2018;31(4):442-449.

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology. Circ Arrhythm Electrophysiol 2019;12(4):e006841.

Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

Kaye DM, Petrie MC, McKenzie S, Hasenfubeta G, Malek F, Post M, Doughty RN, Trochu JN, Gustafsson F, Lang I, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Hausleiter J, Raake P, Jondeau G, Bergmann MW, Spelman T, Aytug H, Ponikowski P, Hayward C, investigators RL-Hs. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail 2019;6(1):62-69.

Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock

Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, Pieri M, Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M, Eckner D, Twerenbold R, Nordbeck P, Salinger T, Abel P, Empen K, Busch MC, Felix SB, Sieweke JT, Moller JE, Pareek N, Hill J, MacCarthy P, Bergmann MW, Henriques JPS, Mobius-Winkler S, Schulze PC, Ouarrak T, Zeymer U, Schneider S, Blankenberg S, Thiele H, Schafer A, Westermann D. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation 2019;139(10):1249-1258.

Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)

Paitazoglou C, Bergmann MW, Vrtovec B, Chamuleau SAJ, van Klarenbosch B, Wojakowski W, Michalewska-Wludarczyk A, Gyongyosi M, Ekblond A, Haack-Sorensen M, Jaquet K, Vrangbaek K, Kastrup J, Investigators S. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE). Eur J Heart Fail 2019;21(8):1032-1041.

The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction

Paitazoglou C, Ozdemir R, Pfister R, Bergmann MW, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker S, Sievert H, Mahfoud F. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention 2019;15(5):403-410.

Antithrombotic Therapy and Device-Related Thrombosis Following Endovascular Left Atrial Appendage Closure

Saw J, Nielsen-Kudsk JE, Bergmann MW, Daniels MJ, Tzikas A, Reisman M, Rana BS. Antithrombotic Therapy and Device-Related Thrombosis Following Endovascular Left Atrial Appendage Closure. JACC Cardiovasc Interv 2019;12(11):1067-1076.

Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN

Sondergaard L, Wong YH, Reddy VY, Boersma LVA, Bergmann MW, Doshi S, Kar S, Sievert H, Wehrenberg S, Stein K, Holmes DR, Jr. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN. JACC Cardiovasc Interv 2019;12(11):1055-1063.

The atrial flow regulator: current overview on technique and first experience

Paitazoglou C, Bergmann MW.Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720919577. doi: 10.1177/1753944720919577. PMID: 32972299

Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN

Ledwoch J, Sievert K, Boersma LVA, Bergmann MW, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts TR, Mazzone P, Foley D, Grygier M, De Potter T, Sievert H; EWOLUTION Investigators. Europace. 2020 Jul 1;22(7):1036-1043. doi: 10.1093/europace/euaa074

Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation

Escher F, Pietsch H, Aleshcheva G, Wenzel P, Fruhwald F, Stumpf C, Westermann D, Bauersachs J, Enseleit F, Ruschitzka F, Nägele H, Laugwitz KL, Haake H, Frey N, Brachmann J, Huber K, Braun-Dullaeus RC, Bergmann MW, Strotmann J, Grönefeld G, Krülls-Münch J, Westenfeld R, Skurk C, Landmesser U, Pieske B, Gross UM, Morawietz L, Schultheiss HP. J Clin Med. 2020 Aug 19;9(9):2689. doi: 10.3390/jcm9092689. PMID: 32825201

One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study

Paitazoglou C, Bergmann MW, Özdemir R, Pfister R, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker S, Sievert H, Mahfoud F; AFR-PRELIEVE Investigators. Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119. Online ahead of print. PMID: 33555114

Lehrbefugnis für das Fach Innere Medizin Charité

Lehrbefugnis für das Fach Innere Medizin UKE

Professor §117 Hamburger Hochschulgesetz